A 3D virtual model of the PKMYT1–PROTAC–CRBN ternary complex depicting how Insilico Medicine’s bifunctional proteolysis-targeting chimera (PROTAC) D16-M1P2 (shown in yellow) inhibits ...
AI Designs a Novel PROTAC from Scratch: Insilico's generative AI platform, Chemistry42, successfully designed a first-in-class PROTAC targeting PKMYT1 by creating an entirely new inhibitor and its ...
SAN FRANCISCO , CA, UNITED STATES, March 30, 2026 /EINPresswire.com/ — Ainnocence, a next-generation AI drug discovery company, announces the commercial ...
Targeted protein degradation has the potential to deliver greater efficacy than conventional receptor antagonists or enzyme inhibitors and address previously undruggable targets. This has driven a ...
Targeted protein degradation via “hijacking” of the ubiquitin-proteasome system using proteolysis targeting chimeras (PROTACs) has evolved into a novel therapeutic modality. The design of PROTACs is ...
PROTACs (Proteolysis Targeting Chimeras) offer a revolutionary strategy to degrade proteins previously considered "undruggable." While the importance of the target protein ligand and linker is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results